Skip to content

PR-Web

Press releases worldwide

  • Home
  • Contact
  • Datenschutzerklärung
  • Legal notice

Author: Firma TissUse

Novel Liver Ring Trial Set to Revolutionize Drug Safety Assessment

Posted on 28. May 2024 by Firma TissUse Posted in Research / Development Tagged adme, clinical, dili, esqlabs, humimic, liver, marking, micro, mps, orion, osp, project, tissuse, UCB, with

In a first-of-its-kind initiative, TissUse (a leader in organ-on-chip technology) announced the commencement of the Liver Ring Trial. This collaborative effort involving ESQLabs (a computational model expert), UCB, a global biopharmaceutical company and initiator of the ring trial, and five […]

Read More

New Multi-Organ-Chip project towards vaccine & drug candidate testing for Tuberculosis

Posted on 7. November 20227. November 2022 by Firma TissUse Posted in General Tagged biotechnology, BMGF, Collaboration, disease model, humimic, mps, Multi-Organ-Chip, Organ-on-a-Chip, research, tissuse, tuberculosis, vaccines

TissUse will receive funding from the Bill & Melinda Gates Foundation to develop a human preclinical lung-liver-lymph node co-culture on a HUMIMIC Chip infectable with Mycobacterium tuberculosis. This collaboration will contribute to the development of Tuberculosis vaccine candidates and treatment. […]

Read More

Philip Morris International and TissUse develop a human aerosol test platform to emulate the entire human respiratory tract

Posted on 21. June 202121. June 2021 by Firma TissUse Posted in Research / Development Tagged bone, bronchial, cell, dosing, hair, humimic, inhalable, liver, nicotine, skin, smoke, stopped, thyroid, tissuse, with

PMI and TissUse have signed a collaboration agreement to utilize PMI’s InHALES technology in combination with TissUse’s proprietary Multi-Organ-Chip (MOC) platform to enable inhalation exposure of functional human tissues in homeostasis at minute scale in vitro. The two partners will […]

Read More

TissUse GmbH appoints Dr. Reyk Horland as new CEO while TissUse’s founder

Posted on 1. October 2020 by Firma TissUse Posted in General Tagged blood, company, energy, humimic, immune, market, network, new, pharmaceutical, platform, research, strong, technology, tissuse, with

On its 10th company anniversary, TissUse GmbH appoints Dr. Reyk Horland, previously VP Business Development, as the new CEO. Reyk Horland has been with TissUse since it was founded in 2010 and has implemented a profitable product business with a […]

Read More

TissUse has been certified under the ISO EN 9001-2015

Posted on 12. December 201912. December 2019 by Firma TissUse Posted in Research / Development Tagged chip, company, dekra, document, iso, management, marx, process, quality, services, systems, technology, testing, tissuse, with

TissUse – the leading pioneer of the Multi-Organ-Chips technology enabling highly predictive substance testing has been awarded the ISO EN 9001-2015. The ISO 9001-2015 is a globally recognized standard that certifies quality management systems focused on ongoing improvements, customer satisfaction and implementing […]

Read More

TissUse Launches New Product Brand HUMIMIC

Posted on 3. June 201911. December 2019 by Firma TissUse Posted in Research / Development Tagged autoplant, berlin, company, cosmetic, customers, device, devices, humimic, new, pharmaceutical, solutions, systems, technology, tissuse, with

TissUse, the Berlin-based pioneers in Human-on-a-Chip developments, have launched their new product brand HUMIMIC. From now on, all of the company’s products will be marketed under this common brand. As a result, TissUse GmbH’s products will have a uniform name […]

Read More

TissUse grants first Smart Hair Transplant (SHT) License in Japan

Posted on 8. April 201911. December 2019 by Firma TissUse Posted in Research / Development Tagged cell, devices, financial, hair, hewitt, medical, prp, sht, smart, technology, therapy, tissuse, transplant, with, wrinkle

For the first time, TissUse has granted development and distribution rights of its existing Smart Hair Transplant (SHT) technology to J. Hewitt, a Japan-based biopharmaceutical company focused on creating transformative regenerative medicine for aesthetic surgery. Under the terms of this […]

Read More

TissUse establishes a liver-endocrine tissues multi-organ model for risk assessment with Bayer

Posted on 3. September 201811. December 2019 by Firma TissUse Posted in Research / Development Tagged bayer, bone, cardiac, cartilage, cells, fatty, hair, kidney, liver, new, power, skin, thyroid, tissuse, with

TissUse has signed a collaboration agreement with Bayer to develop a highly innovative liver-endocrine tissues assay using TissUse’s Multi-Organ-Chip (MOC) technology. Under the terms of the collaboration agreement, TissUse will join forces with Bayer to develop a novel mechanistic in […]

Read More

TissUse announces new partnership with leading pharmaceutical company to develop applications for its Multi-Organ-Chip platform in drug research and development

Posted on 5. March 201811. December 2019 by Firma TissUse Posted in General Tagged antibodies, antibody, aspect, cardiac, cartilage, cell, cells, dosing, hair, kidney, liver, roche, skin, tissuse, with

TissUse and Roche have signed a cooperating agreement to develop human-relevant in vitro assays based on TissUse’s Multi-Organ-Chip technology. Under the terms of the collaboration agreement, TissUse will provide its Multi-Organ-Chip (MOC) technology as a highly versatile tool to develop […]

Read More

TissUse reports progress made in collaboration with AstraZeneca to use Microphysiological Systems in the drug development process

Posted on 22. January 201811. December 2019 by Firma TissUse Posted in Research / Development Tagged biotech, cell, chemicals, danielson, diabetes, disease, imed, insulin, mps, new, patients, study, testing, tissuse, with

TissUse continues their successful collaboration with AstraZeneca to establish relevant Microphysiological System (MPS) models based on TissUse’s Multi-Organ-Chip technology. As part of the collaboration, the teams have explored the unmet need for a physiologically relevant human ex-vivo type 2 diabetes […]

Read More

Copyright 2016. All rights reserved.


Back To Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more